The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.50 USD
+0.96 (0.91%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $106.46 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.50 USD
+0.96 (0.91%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $106.46 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
DaVita (DVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.
Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?
by Zacks Equity Research
DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) Specialty Health unit is likely to drive the company's top line in the third quarter of fiscal 2018.
H&R Block (HRB) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Core business focus is likely to drive H&R Block's (HRB) Q2 earnings although macroeconomic challenges remain impediments
Will CooperVision Drive Cooper Companies' (COO) Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fourth quarter is expected to gain from strength in the CVI & CSI segments.
Only 4 Dental Stocks to Buy Amid MedTech Regulatory Woes
by Zacks Equity Research
After a stellar five-year run on the bourse, the performance of the dental industry has taken a hit in the last two years.
Patterson Companies (PDCO) Q2 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies' (PDCO) solid dental segment is a positive. The company anticipates troubles in its technology equipment business to persist through fiscal 2018.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.
What's in the Cards for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.
Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.
Why Is Cooper Companies (COO) Down 7.7% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Dental Faces Regulatory Challenges: Only 5 Stocks to Pick
by Zacks Equity Research
Owing to the adversities in the medical universe, market watchers have adopted a bearish stance toward the dental space. These are the only five dental stocks that are expected to beat the ongoing MedTech gloom.
Top Ranked Momentum Stocks to Buy for September 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 8th:
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Why Is Cooper Companies (COO) Up 7.9% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can the Rally in Cooper Companies (COO) Shares Continue?
by Zacks Equity Research
Cooper Companies Inc (COO) has been on the move lately as the stock has risen by 17.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
Cooper (COO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report second-quarter fiscal 2017 results after the market closes on Jun 1.
Align Technology (ALGN) Rises: Stock Adds 7.5% in Session
by Zacks Equity Research
Align Technology, Inc. (ALGN) rose over 7% in the last trading session.
Cooper Companies (COO) Increase Share Repurchase Program
by Zacks Equity Research
The Cooper Companies, Inc. (COO) recently announced that it has approved a $500.0 million increase in its ongoing share repurchase program.
Cooper Companies (COO) Receives ISO 15189 Accreditation
by Zacks Equity Research
The Cooper Companies Inc. (COO) announced that its London and Nottingham-based laboratories received the International Organization for Standardization 15189 accreditation.
The Cooper Companies (COO) Beats Earnings Estimates in Q1
by Zacks Equity Research
The Cooper Companies Inc.(COO) reported adjusted earnings of $1.93 in first-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 7 cents and improving 5.5% on a year-over-year basis.
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.
Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.